Strados Labs

02/17/2026

Digital health technologies are redefining respiratory care—expanding access through home monitoring and decentralized clinical trials that bring participation closer to patients.

A recent article from AJMC - The American Journal of Managed Care underscores both the promise and complexity of this shift. Experts agree that digital tools must be validated not only for accuracy, but also for how well they integrate into patients’ daily lives and clinical workflows. Learn more: https://bit.ly/4nJSd7w

Our clinically validated RESP® Biosensor reflects that approach. It continuously and passively captures lung sounds in a wireless, patient-friendly form factor that integrates into daily life. By collecting a robust combination of respiratory and physiological data, including time-stamped cough and wheeze events, it gives clinicians a more complete view of respiratory health in both care and research settings.

Digital health technologies enhance respiratory care through decentralized clinical trials and home monitoring, expanding access and improving patient engagement.

02/12/2026

We’re excited to welcome Matthew McCarty as Chief Commercial Officer at Strados Labs!

Matt brings nearly 20 years of experience across life sciences and clinical trials, including leadership roles at global CROs and senior executive experience in the clinical trial endpoint market. Throughout his career, he has partnered closely with pharmaceutical sponsors, biotechnology companies, and CROs to support the adoption of novel endpoints and decentralized data collection in global studies.

At Strados, Matt will lead sales, marketing, partnerships, and commercial strategy as we expand the RESP® Platform from objective cough and lung sound monitoring into a broader ecosystem of respiratory trial solutions.

From Matt: “I have long been impressed by the Strados Labs team and the RESP® Platform — not only for its technical innovation but for its clear differentiation in the clinical trial endpoint landscape. The ability to objectively and continuously measure cough and lung sounds addresses critical gaps in how respiratory diseases are evaluated in research today. I see tremendous opportunity to help sponsors integrate these solutions to generate more reliable data and ultimately improve the probability of clinical success.”

Please join us in welcoming Matt to the leadership team!

02/11/2026

Early detection and ongoing assessment continue to be central challenges in COPD care.

The 2026 update from the Global Initiative for Chronic Obstructive Lung Disease, summarized by Pulmonology Advisor, emphasizes earlier identification of disease progression, multimorbidity management, and the growing role of digital and AI-enabled approaches in COPD evaluation.

Read the update here: https://bit.ly/4qVEX1E

These priorities reinforce the need for tools that extend respiratory insight beyond episodic clinic visits—an area where continuous, real-world respiratory data may play an increasingly important role.

The GOLD COPD Update 2026 provides updated guidance on case-finding, disease activity, exacerbation management.

02/05/2026

In a recent conversation with Dr. Sabiha Hussain, MD, MPH, principal investigator of our cystic fibrosis study at Rutgers Robert Wood Johnson Medical School, we discussed the challenges of monitoring respiratory health in patients with cystic fibrosis once they leave the clinic.

Our discussion explored the limitations of episodic assessments, the importance of detecting subtle changes in lung health earlier, and why low-effort, home-based monitoring may be particularly meaningful for patients managing a chronic, high-burden disease like CF.

We also talked about how continuous lung sound monitoring could complement traditional measures such as FEV1 and patient-reported outcomes, and what it takes to design monitoring approaches that are both clinically relevant and realistic for patients to use over time.

Read the full Q&A with Dr. Hussain: https://stradoslabs.com/q-a-with-dr-sabiha-hussain-professor-of-medicine-at-robert-wood-johnson-medical-school-rutgers-health/

02/03/2026

Respiratory illness season remains a significant public health challenge, with influenza, COVID-19, and RSV continuing to drive hospitalizations and severe outcomes each year.

The Centers for Disease Control and Prevention recently released its Respiratory Illness Season Toolkit, designed to help public health partners, clinicians, and communities prepare for and respond to respiratory illness risk. The toolkit includes communication resources, prevention guidance, and materials to support education and outreach before and during peak respiratory virus season.

Explore the toolkit here: https://www.cdc.gov/respiratory-viruses/php/toolkit/index.html

As respiratory health continues to be a year-round concern, efforts that improve awareness, surveillance, and early insight into symptoms play an important role in protecting patients and supporting more proactive care.

A partner toolkit with essential respiratory illness resources and communication materials.

01/28/2026

Announcing COPD Exacerbation Study!

Amid persistently high readmission rates among patients with chronic obstructive pulmonary disease (COPD), we’re excited to announce a new observational research study in collaboration with Jefferson Health evaluating the use of our FDA 510(k) cleared RESP® Biosensor.

The SHORE study will assess the feasibility of continuous, home-based monitoring of cough and lung sounds (including wheeze and rhonchi) following COPD exacerbations. Enrollment started in January.

COPD exacerbations are a leading cause of hospitalization and readmission, yet clinicians often have limited insight into respiratory status once patients return home. The study will explore whether passive, stethoscope-based wearable monitoring can help extend respiratory assessment beyond the clinic and into daily life, where early changes may first appear.

Findings from the study are expected to inform future research into remote lung sound monitoring for COPD and other chronic respiratory diseases.

🔗 Read the full press release: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/strados-labs-announces-study-evaluating-remote-lung-sound-monitoring-1131102

01/22/2026

Save the date: SCOPE Summit | February 2–5 | Orlando

Now in its 17th year, SCOPE 365 brings together leaders across pharma, biotech, CROs, sites, and technology to discuss how clinical trials are evolving amid increasing complexity, data demands, and patient expectations.

Our CEO & Founder Nick Delmonico and Global Director Shane Krauss plan to attend and look forward to exchanging perspectives on how real-world data, digital tools, and new monitoring approaches can support more effective, patient-centered endpoints.

Register for the event at: https://www.scopesummit.com/

01/19/2026

Today we recognize Martin Luther King Jr. and reflect on his leadership, courage, and commitment to justice and equality.

Dr. King's work reminds us of the importance of integrity, responsibility, and showing up for others—values that remain relevant across communities.

01/14/2026

Protecting Patient Privacy: Built Into Our Technology

At Strados Labs, privacy isn’t an afterthought. It’s built into the RESP® Platform from the start. Designed to capture internal lung sounds, our biosensor avoids ambient noise and background speech common with free-field mics in phones or wearables.

We add further safeguards with:
• Speech obfuscation in our cloud platform using voice activity detection (VAD) filters and other methods to remove incidental speech
• End-to-end encryption to secure data in transit and at rest

These protections ensure we advance respiratory care while safeguarding patient confidentiality and trust.

Learn more: https://stradoslabs.com/

01/12/2026

Strados Labs will be in San Francisco this week, January 12–15, for the 44th Annual JPM Healthcare Conference, a week when the entire healthcare ecosystem seems to converge in one place!

JPM has long been a place where investment, innovation, and real momentum in healthcare converge. This year’s conversations are expected to focus heavily on how emerging technologies, particularly AI-driven approaches, are shaping drug development, diagnostics, and scalable digital health solutions.

We’re looking forward to connecting with industry leaders, innovators, and investors who are thinking deeply about how objective, real-world data can strengthen clinical research, support better decision-making, and ultimately improve patient outcomes, especially in respiratory health.

If you’ll be in San Francisco for JPM, let’s connect! https://www.jpmorgan.com/about-us/events-conferences/health-care-conference

We aim to be the most respected financial services firm in the world, serving corporations and individuals in more than 100 countries.

01/08/2026

We’re heading to San Francisco next week for one of the most important events in healthcare.

Nick Delmonico, CEO and Co-founder of Strados Labs, will be attending the J.P. Morgan Healthcare Conference from January 12–15.

Nick will be on the ground connecting with industry leaders, investors, and partners to discuss innovation in respiratory monitoring, digital health, and clinical research. If you’ll be there and would like to connect, please feel free to message him!

01/06/2026

ICYMI: Cough is becoming a digital endpoint in more clinical trials, but how cough events are processed is just as important as the devices capturing them.

Our recent whitepaper outlines a key design decision for sponsors and research teams: choosing between edge processing (on-device, real-time ML analysis) and cloud processing (analysis of raw audio on secure servers with ML + human review).

As the paper explains, this choice carries significant implications for scientific integrity, regulatory acceptance, and the ability to conduct retrospective quality checks. Cloud processing retains raw audio, supports FDA-recognized human annotation, and enables full audit trails—capabilities essential for reliable, defensible clinical data.

Read the whitepaper: https://stradoslabs.com/data-processing-architectures-for-cough-monitoring-the-case-for-cloud-processing/

This whitepaper highlights an important yet often overlooked aspect of cough monitoring: the data processing architecture that supports how cough events are